Cheang, M C UBliss, J MViale, GSpeirs, VPalmieri, CShaaban, ALønning, P EMorden, JPorta, NJassem, Jvan De Velde, C JRasmussen, B BVerhoeven, DBartlett, J M SCoombes, R CPathIES Sub-Committee2018-07-302018-07-302018-02Cheang, M C U, Bliss, J M, Viale, G, Speirs, V, Palmieri, C, Shaaban, A, Lønning, P E, Morden, J, Porta, N, Jassem, J, van De Velde, C J, Rasmussen, B B, Verhoeven, D, Bartlett, J M S, Coombes, R C & PathIES Sub-Committee 2018, 'Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES) : PathIES', Breast Cancer Research and Treatment, vol. 168, no. 1, pp. 169-178. https://doi.org/10.1007/s10549-017-4543-70167-6806PubMedCentral: PMC5847042ORCID: /0000-0002-0602-4666/work/72631318http://hdl.handle.net/2164/10831This work was supported by Cancer Research UK (C37/A8434) and Pfzer (GA9001DP). Cancer Research UK also providedprogramme grants to the Institute of Cancer Research Clinical Trials and Statistics Unit and the Division of Cancer at Imperial College London. This study was supported by Imperial Experimental Cancer Medicine Centre, Imperial Biomedical Research Centre and Imperial Cancer Research UK Centre. MCUC is supported by the Cancer Research UK Core grant (Grant Number C1491/A15955).10877955engSDG 3 - Good Health and Well-beingJournal Articlebreast canceraromataseprognosisR MedicineCancer Research UKC37/A8434C1491/A15955RJournal article10.1007/s10549-017-4543-71681